To fund GSK’s R&D efforts she froze the dividend at 80p per share for yonks. In 2022, it was slashed to 44p then to 42p the ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...

(Reuters) - The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on ...

British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...